- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06719102
Mothers and CareGivers Investing in Children Study 2.0 (MAGIC 2)
Mothers and CareGivers Investing in Children: MAGIC 2.0
The study will use a longitudinal, randomized control trial design to determine intervention impact on parent and child behaviors, and infant health. The two intervention groups include: 1) MAGIC-FEED+; and 2) MAGIC-SAFE. This trial is an efficacy trial of the MAGIC-FEED and MAGIC-SAFE program that has been successfully implemented with families as part of the MAGIC 1.0 program trial (IRB#: 2015040017).
- The primary aim is to investigate each intervention's impact on infant BMIZ at 13 months.
- The investigators will also assess the effect of MAGIC-FEED on caregiver nutrition knowledge and feeding practices, responsive feeding, infant diet, and child self-regulatory abilities and assess how these factors impact child self-regulation of eating and adiposity.
- Finally, the investigators will determine if the interventions demonstrate the factors necessary to be a successful intervention as determined by the RE-AIM and PRISM frameworks.
Study Overview
Status
Intervention / Treatment
Detailed Description
Obesity is a significant public health problem and risk begins early in life. In the US, over 19% of children ages 2-19 have obesity with 6% of these children classified with severe obesity. Obesity prevalence is lower among 2- to 5-year-old children (13.4%); however, by age 6, one in 5 children has obesity. Rapid weight gain over the first year of life is associated with overweight or obesity in toddlers and young children, which then tracks across the life course. It is critical to intervene on modifiable factors early in life to support healthy growth and prevent obesity. This trial is implemented across the first year in this population to support child diet quality, self-regulatory skills related to eating and growth to prevent obesity.
Interventions during the first year of life have been implemented to prevent child obesity. Most focus on breast and bottle feeding during the first 6 months or feeding across infancy. Few have demonstrated lasting effects beyond infancy on a relative body size measure that accounts for height such as BMIZ, and none have reported effects on long-term adiposity measured with a sensitive assessment tool or have successfully impacted long-term relative body size or adiposity. Further, prior RCTs have predominately been conducted via home visits. MAGIC 2.0 uses a virtual platform which will allows us to leverage the well-established effectiveness of home visiting to be accessible to caregivers with young children.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Deborah Jacobvitz, PhD
Study Contact Backup
- Name: Elizabeth Widen, PhD, RD
- Phone Number: 512-471-0941
- Email: widen.lab@austin.utexas.edu
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78723
- Recruiting
- Dell Pediatric Research Institute
-
Contact:
- Elizabeth Widen
- Email: widen.lab@austin.utexas.edu
-
Austin, Texas, United States, 78712
- Not yet recruiting
- Sarah M. & Charles E. Seay Building
-
Contact:
- Deborah Jacobvitz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A singleton infant 3-9 weeks of age, born ≥37 weeks gestation.
- The mother and other caregiver must be at least 18 years of age.
- The infant must live with the mother.
- Lives within the Austin metropolitan area.
- English or Spanish speaking.
- The primary caregiver must identify as the mother.
Exclusion Criteria:
- Infant diagnosed with major physical disabilities and/or medical condition that affects feeding and growth, and/or born <37 weeks gestation.
- Infant experienced NICU stay >7 days.
- Twins, triplets, or other multiples.
- Mothers and/or other caregivers younger than 18 years old.
- Mothers that do not consent to being video recorded with their baby.
- Families that do not speak either English or Spanish will be excluded from this study. Families that only speak English or Spanish, or families that speak English or Spanish and another language, will be accepted.
- Do not plan to remain in Austin area for the next two years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: MAGIC-SAFE
Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc.
The intervention is delivered via virtual visits, binder, website and newsletters.
|
Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc.
The intervention is delivered via virtual visits, binder, website and newsletters.
|
|
Experimental: MAGIC-FEED
Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines.
The intervention is delivered via virtual visits, binder, website and newsletters.
|
Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines.
The intervention is delivered via virtual visits, binder, website and newsletters.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Infant Body Mass Index Z-score (BMIZ) at 13 and 24 months
Time Frame: 13 & 24 months
|
Assessed via anthropometrics and WHO Child Growth Standards.
|
13 & 24 months
|
|
Infant dietary quality index
Time Frame: 0-13 months
|
Infant dietary quality index (IDQI) score with higher scores indicating higher dietary quality (Au et al.
J Nutr 2023, 153(3): 741-748).
Calculated with questionnaire data from an adapted Infant Feeding Practices III Food Frequency Questionnaire.
|
0-13 months
|
|
Infant self-regulation during feeding
Time Frame: 0-13 months
|
Infant self-regulation during feeding coded from video observation via the Nursing Child Assessment Feeding Scale.
|
0-13 months
|
|
Eating self-regulation
Time Frame: 24 months
|
Assessed via 'Eating in the Absence of Hunger' experiment using standard protocols (Asta et al.
Pediatrics 2016;137(5):e20153786).
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Caregiver nutrition knowledge
Time Frame: 0-24 months
|
Caregiver nutrition knowledge assessed by the Infant Feeding Education Questionnaire.
|
0-24 months
|
|
Caregiver sensitivity
Time Frame: 0-24 months
|
Caregiver responsive feeding/sensitivity with higher scores indicating greater sensitivity.
Assessed by Chatoor's Feeding Scale, Hazen Sensitivity Scale and Nursing Child Assessment Feeding Scale.
|
0-24 months
|
|
Solid food introduction timing
Time Frame: 0-8 months
|
Timing of solid food introduction (<6 mo, >=6 mo).
Assessed by the adapted Infant Feeding Practices III Questionnaire.
|
0-8 months
|
|
Percentage body fat
Time Frame: 13 & 24 months
|
Percentage body fat assessed via DXA.
|
13 & 24 months
|
|
Proportion with BMIZ >=95%ile
Time Frame: 13 & 24 months
|
High BMI at 13 & 24 months
|
13 & 24 months
|
|
BMIZ change from 3 wk to 24 months
Time Frame: 0-24 months
|
BMIZ change from 3 wk to 24 months assessed via anthropometrics and WHO Child Growth Standard.
|
0-24 months
|
|
Child self-regulation
Time Frame: 24 months
|
Inhibitory control assessed via behavioral rating from the Barrier Box Tax with higher scores indicating greater regulation.
|
24 months
|
|
Caregiver infant feeding practices
Time Frame: 0-24 months
|
Assessed by the Feeding Practices and Structure Questionnaire.
|
0-24 months
|
|
Baby Eating Behavior
Time Frame: ~ 8 months
|
Infant eating behaviors assessed via the Baby Eating Behavior Questionnaire.
|
~ 8 months
|
|
Child Eating Behavior
Time Frame: 24 months
|
Child eating behaviors assessed via the Children's Eating Behavior Questionnaire.
|
24 months
|
|
Duration of exclusive breastfeeding
Time Frame: 0-24 months
|
Duration of exclusive breastfeeding assessed via the adapted Infant Feeding Practices III Questionnaire.
|
0-24 months
|
|
Sugary beverages before 12 months
Time Frame: 0-12 months
|
Introduction of sugary beverages prior to 12 months.
Assessed via the adapted Infant Feeding Practices III questionnaire.
|
0-12 months
|
|
Child self-regulation
Time Frame: 13 months
|
Assessed by the Brief Infant Toddler Social Emotional Assessment (BITSEA) with higher scores indicating greater self-regulation.
|
13 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Widen, PhD, RD, UT Austin
- Principal Investigator: Deborah Jacobvitz, PhD, UT Austin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UT Austin IRB#STUDY00005620
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infant Growth
-
Laboratorios OrdesaUniversidad de GranadaUnknown
-
Biostime (Changsha) Nutrition Foods LimitedShenzhen UniversityNot yet recruiting
-
Société des Produits Nestlé (SPN)Completed
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Colorado... and other collaboratorsCompletedInfant Growth | Infant Gut Microbiome | Infant Body FatUnited States
-
University of ManitobaJohns Hopkins University; University Health Network, Toronto; University of California... and other collaboratorsActive, not recruitingMaternal Health | Infant Growth | Infant NutritionCanada
-
Nutricia ResearchTerminatedInfant Growth | Parent and Infant User ExperienceNetherlands
-
Ethiopian Public Health InstituteWageningen University; Micronutrient InitiativeCompletedGrowth Acceleration | Infant MorbidityEthiopia
-
University Rovira i VirgiliHospital Universitari Joan XXIII de Tarragona.; Institut Investigacio Sanitaria... and other collaboratorsCompletedHealthy | Growth | Infant | NutritionSpain
-
University GhentInstitut de Recherche en Sciences de la Sante, Burkina Faso; NutrisetCompletedGrowth Retardation | Infant MorbidityBurkina Faso
-
DSM Nutritional Products, Inc.AccelovanceCompletedGrowth | Tolerance | Infant DevelopmentUnited States
Clinical Trials on MAGIC-SAFE
-
Barbara Ann Karmanos Cancer InstituteRecruitingStage I Breast Cancer | Stage II Breast Cancer | Ductal Carcinoma in Situ | Stage III Breast CancerUnited States
-
The University of Texas Health Science Center,...American Heart AssociationNot yet recruitingPhysical ActivityUnited States
-
StereotaxisOsypka AGRecruitingArrhythmias, CardiacPoland, Netherlands, Denmark, Lithuania
-
Stony Brook UniversityUnknown
-
University of MinnesotaCompleted
-
Instituto PalacioseCareYou InnovationCompleted
-
Technical University of MunichCompletedHeart Failure | Sudden Cardiac DeathGermany
-
University of Alabama at BirminghamRecruitingAutism | Pervasive Developmental DisorderUnited States
-
University of Alabama at BirminghamCompleted
-
Yaffa Golan, Ltd.CompletedDiabetes | Peripheral Vascular DiseaseIsrael